The relationship between hyperpolypharmacy and one-year outcomes in patients with critical limb ischemia undergoing below-knee endovascular therapy

Basit Öğe Kaydı
dc.contributor.authorAltunova, Mehmet
dc.contributor.authorGulmez, Recep
dc.contributor.authorKarakayali, Muammer
dc.contributor.authorGurbak, Ismail
dc.contributor.authorTasbulak, Omer
dc.contributor.authorDemirci, Gokhan
dc.contributor.authorGuler, Arda
dc.date.accessioned2024-04-24T17:14:45Z
dc.date.available2024-04-24T17:14:45Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground Critical limb ischemia (CLI) patients take too many medications because they are elderly and frail patients with multiple comorbidities. Polypharmacy is associated with frailty, although its prognostic significance in CLI patients is unknown. In this study, we aimed to determine the prevalence of hyperpolypharmacy among adults with CLI and its effect on 1-year amputation and mortality.Methods A total of 200 patients with CLI who underwent endovascular therapy (EVT) for below-knee (CTC) lesions were included in this study. Hyperpolypharmacy was defined as using >= 10 drugs. Patients were divided into two groups according to the presence of hyperpolypharmacyResults We detected hyperpolypharmacy in 66 patients. The incidence of 1-year amputation [24 (36.4) versus 12 (9), p<.001] and mortality [28 (42.4) versus 12 (9), p<.001] were higher in patients with hyperpolypharmacy. Univariate and multivariate cox regression analyses were used to determine the independent predictors of amputation and mortality. In the receiver operating characteristic curve analysis, the cut-off value was defined as 10 or more drug use was able to detect the presence of 1-year mortality with 67.5% sensitivity and 79.4% specificity. The Kaplan-Meier method showed a significant difference (rank p <.001 between log groups), and hyperpolypharmacy was associated with 1-year amputation and mortality.Conclusion Hyperpolypharmacy was significantly associated with 1-year mortality and major amputation in CLI patients. Hyperpolypharmacy can be a valuable aid in patient risk assessment in the CLI.en_US
dc.identifier.doi10.1177/17085381231193496
dc.identifier.issn1708-5381
dc.identifier.issn1708-539X
dc.identifier.pmid38095298
dc.identifier.scopus2-s2.0-85179740010
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1177/17085381231193496
dc.identifier.urihttps://hdl.handle.net/11468/18173
dc.identifier.wosWOS:001126873800001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofVascular
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHyperpolypharmacyen_US
dc.subjectCritical Limb Ischemiaen_US
dc.subjectEndovascular Therapyen_US
dc.subjectMajor Amputationen_US
dc.subject1-Year Mortalityen_US
dc.titleThe relationship between hyperpolypharmacy and one-year outcomes in patients with critical limb ischemia undergoing below-knee endovascular therapyen_US
dc.titleThe relationship between hyperpolypharmacy and one-year outcomes in patients with critical limb ischemia undergoing below-knee endovascular therapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu